Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described indazole macrocycles acting as stimulator of interferon genes protein (STING; TMEM173) antagonists reported to be useful for the treatment of cancer, autoimmune diseases, inflammatory, neurological, metabolic, cardiovascular and eye disorders.
Synnovation Therapeutics Inc. has identified phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer, PIK3CA-related overgrowth spectrum (PROS), congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities.
Interline Therapeutics Inc. has synthesized receptor-interacting serine/threonine-protein kinase 2 (RIPK2; RIP-2) inhibitors reported to be useful for the treatment of cancer, inflammation, allergy, fibrosis, autoimmune, cardiovascular and metabolic diseases.
Humanwell Healthcare (Group) Co. Ltd. has disclosed compounds acting as phosphodiesterase PDE4 inhibitors, particularly PDE4B, reported to be useful for the treatment of respiratory, gastrointestinal, inflammatory, dermatological, ophthalmic and neurological disorders, transplant rejection and cancer.
Researchers from three California-based institutions are seeking patent protection for systems, devices and methods that allow brain-controlled limb movement and sensation.
Activon Co. Ltd. has described compounds acting as reactive oxygen species (ROS) production inhibitors reported to be useful for the treatment of aging, atopic dermatitis, cardiovascular disorders, cancer, hepatitis, hepatobiliary diseases, neurodegeneration and rheumatoid arthritis.
University of Alberta has divulged 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of viral infections.
Kymera Therapeutics Inc. has identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding agent coupled to probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and/or polybromo-1 (PB1) protein targeting moiety via a linker reported to be useful for the treatment of cancer, viral infection, neurodegeneration, liver, metabolic, cardiovascular, genetic and inflammatory disorders, among others.
RSS
